AI Article Synopsis
- GERD is a major gastrointestinal disorder that has gained more attention due to better understanding and treatment options in recent years.
- Advances in treatments like proton pump inhibitors have altered how doctors diagnose and manage GERD, but the condition remains complex, with some patients experiencing more difficult symptoms.
- The article focuses on current challenges in dealing with GERD, especially for patients who have troublesome symptoms that don't respond to standard therapies.
Article Abstract
Gastroesophageal reflux disease (GERD) is one of the most common problems in gastrointestinal disorders. With the increase in our understanding on the pathophysiology of GERD along with the development of proton pump inhibitors, the diagnostic and therapeutic approaches to GERD have changed dramatically over the past decade. However, GERD still poses a problem to many clinicians since the spectrum of the disease has evolved to encompass more challenging presentations such as refractory GERD and extraesophageal manifestations. This has led to significant confusion regarding the optimal approach to these patients. This article aims to discuss current issues on GERD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4166/kjg.2014.64.3.127 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardioesophageal Reflex. Should it trigger clinician's response?
Am J Med
January 2025
Professor of Medicine, Department of Cardiology, Tufts Medical Center, (Tufts University School of Medicine), Boston, MA 02111, USA. Electronic address:
Cardiologists and gastroenterologists often encounter the coexistence of symptoms and functional abnormalities, but determining causation is more difficult. In 1962 Smith and Papp first coined the term "linked angina". Their statement was preceded by the experiment whereby increase in bile duct pressure elicited the typical chest pain in patients with ischemic heart disease.
View Article and Find Full Text PDFXanomeline-Trospium for Adults with Schizophrenia Experiencing Acute Psychosis: A Systematic Review and Meta-analysis of Safety and Tolerability Outcomes.
Pharmacopsychiatry
January 2025
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
The United States Food and Drug Administration approved the xanomeline-trospium combination in September 2024 for treating schizophrenia, based in part on three double-blind, randomized placebo-controlled trials in adults with schizophrenia experiencing acute psychosis. This random-effects model pairwise meta-analysis of those three trials found that xanomeline-trospium was comparable to placebo in terms of all-cause discontinuation, discontinuation rate due to adverse events, Simpson-Angus Scale score change, Barnes Akathisia Rating Scale score change, body weight change, body mass index change, blood pressure change, serum total cholesterol change, blood glucose change, QTc interval changes, and the incidence of headache, somnolence, insomnia, dizziness, akathisia, agitation, tachycardia, gastroesophageal reflux disease, diarrhea, increased weight, and decreased appetite. However, xanomeline-trospium was associated with a higher incidence of at least one adverse event, dry mouth, hypertension, nausea, vomiting, dyspepsia, and constipation, and increased serum triglyceride compared with placebo.
View Article and Find Full Text PDFRisks of anti- therapy and long-term therapy with antisecretory drugs.
World J Gastroenterol
January 2025
Department of Therapy, North Caucasus State Academy, Cherkessk 369000, Russia.
() infection has a protective effect on gastroesophageal reflux disease (GERD). Both of these diseases have a very high incidence and prevalence. As a result, GERD often recurs after anti- therapy.
View Article and Find Full Text PDFPrevalence and Severity of Gastroesophageal Reflux Disease in Indian Children Presenting with Symptoms of Acid Reflux: A Real-world Evidence Study.
Turk Arch Pediatr
January 2025
Department of Pediatrics, Apollo Children's Hospital, Chennai, Tamil Nadu.
Comparative study of clinical efficacy of laparoscopic proximal gastrectomy with double-channel anastomosis and tubular gastroesophageal anastomosis.
World J Gastrointest Surg
January 2025
Department of Gastrointestinal Surgery, The Second People's Hospital of Lianyungang, Lianyungang 222000, Jiangsu Province, China.
Background: According to statistics, the incidence of proximal gastric cancer has gradually increased in recent years, posing a serious threat to human health. Tubular gastroesophageal anastomosis and double-channel anastomosis are two relatively mature anti-reflux procedures. A comparison of these two surgical procedures, tubular gastroesophageal anastomosis and double-channel anastomosis, has rarely been reported.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!